◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocks › DSGN

Design Therapeutics, Inc. (DSGN) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-07-16

Design Therapeutics, Inc. (DSGN) operates in the Biotechnology industry and is headquartered in Carlsbad, United States with about 54 employees. Its market capitalization is roughly $844 million. In the fiscal year ended 2025-12-31, DSGN reported $0M in revenue and ($70M) in net income.

Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States.

Interactive charts & full statements →

DSGN Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Revenue$0M$0M$0M$0M
Operating Income (EBIT)($80M)($62M)($78M)($68M)
Net Income($70M)($50M)($67M)($63M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

DSGN Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-03-312025-12-312025-09-302025-06-302025-03-31
Total Revenue$0M$0M$0M$0M$0M
Operating Income (EBIT)($20M)($18M)($19M)($22M)($20M)
Net Income($18M)($16M)($17M)($19M)($18M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

DSGN Free Cash Flow History

DSGN Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Assets$226M$252M$290M$341M
Total Liabilities$14M$10M$12M$14M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive DSGN viewer.

Other Companies in Biotechnology

← DSACAll stocksDSGR →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.